

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

|   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No equalities issues were identified during the scoping process.  |

|   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| N/A   |

|  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| N/A  |

|  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
| No additional stakeholders related to potential equalities issues were   |

identified during the scoping process.

**Approved by Associate Director (name):** Linda Landells

**Date:** 3 June 2020